Pharma donations to patient groups in Canada are shrouded in mystery
Donation data reported on websites by drug makers and patient advocacy groups in Canada that receive industry funding is “haphazard, inconsistent and incomplete.”
D onation data reported on websites by drug makers and patient advocacy groups in Canada that receive industry funding is “haphazard, inconsistent and incomplete,” underscoring the difficulties in deciphering the influence these companies may have on patient interests, a new analysis finds. Specifically, information about the value of donations made by drug companies, the years in which contributions were given, and the percent of income the money represented for patient groups was limited. Consequently, donations made and received often could not be matched, according to the analysis in the I
Explore this link on the map →related reading
- Pharma Virumque | Slate Star Codexslatestarcodex.com
- The pharma industry from Paul Janssen to today: why drugs got harder to develop and what we can do about it | Alex’s blogatelfo.github.io
- What a time to be an oncologist - by Olivia Webb Kosloffacutecondition.com
- The 23andMe Deal - Cremieux Recueilcremieux.xyz
- Sunshine UKwhopaysthisdoctor.org
- Why are our medicines so expensive? Spoiler: Not for the reasons you are being told… - PMCncbi.nlm.nih.gov
- We wish we’d written that: STAT staffers' favorite stories of 2022statnews.com
- Checking your browser - reCAPTCHAncbi.nlm.nih.gov
- Biotech’s Lost Archive | IFPifp.org
- Some questions about biotech that I find interesting | Alex’s blogatelfo.github.io
- A primer for academic entrepreneurs on academic-industrial partnerships | Nature Communicationsnature.com
- A primer for academic entrepreneurs on academic-industrial partnerships | Nature Communicationsnature.com